Skip to main content

University of Maryland School of Medicine Professor Dr. Curt Civin Receives 2015 Mentor Award from the American Society of Hematology

November 23, 2015

Curt Civin

Physician-Scientist Honored for His Sustained Commitment to Training Early-Career Hematologists

Curt Civin, MD, Professor in the Departments of Pediatrics and Physiology, Director of the Center for Stem Cell Biology and Regenerative Medicine, and Associate Dean for Research, and at the University of Maryland School of Medicine (UM SOM), was one of two physicians to receive the American Society of Hematology’s (ASH) 2015 Mentor Award, which honors outstanding commitment to the training and career development of early-career hematologists.

The award was established in 2006 to recognize hematologists who have excelled in mentoring trainees and colleagues. Each year, ASH recognizes two outstanding mentors who have had a significant impact on their mentees’ careers and, through this, have advanced hematological research and patient care.

Dr. Civin has had a long, distinguished career. He discovered CD34+ lympho-hematopoietic stem-progenitor cells, opening entirely new directions in stem cell, leukemia, immunology, and transplantation research. He also developed the first successful stem cell therapy emanating from basic research, as proved in his own patients. CD34+ was the first and is still the best marker for hematopoietic stem-progenitor cells.

Dr. Civin received a BA in Biology/Independent study from Amherst College in 1970 and an MD from Harvard University in 1974. After completing his pediatric residency at the Boston Children’s Hospital Medical Center, he did a fellowship in pediatric hematology-oncology at the National Cancer Institute (NCI). He arrived at UM SOM in 2009 after more than three decades at the Johns Hopkins University School of Medicine.

As a longstanding member of ASH, Dr. Civin has served on multiple committees and on the editorial board of the group’s journal, Blood. He has served on the editorial boards of nine other scientific journals and served as editor-in-chief of the journal Stem Cells from 2000 to 2007. He is a member of the American Association for the Advancement of Science, the American Society for Cancer Research and the American Society of Clinical Oncology.

“Curt Civin is not only a superior researcher, he is an exceptional teacher,” said Dean E. Albert Reece, MD, PhD, MBA, who is also Vice President of Medical Affairs, the University of Maryland and the John Z. and Akiko Bowers Distinguished Professor. “His commitment to the next generation has yielded great benefit, and serves as an inspiration to our faculty as a model for combining research, treatment and education.”

About the American Society of Hematology

The American Society of Hematology is the world’s largest professional society concerned with the causes and treatment of blood disorders. Its mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

About the University of Maryland School of Medicine

The University of Maryland School of Medicine was chartered in 1807 and is the first public medical school in the United States and continues today as an innovative leader in accelerating innovation and discovery in medicine. The School of Medicine is the founding school of the University of Maryland and is an integral part of the 11-campus University System of Maryland. Located on the University of Maryland’s Baltimore campus, the School of Medicine works closely with the University of Maryland Medical Center and Medical System to provide a research-intensive, academic and clinically based education. With 43 academic departments, centers and institutes and a faculty of more than 3,000 physicians and research scientists plus more than $400 million in extramural funding, the School is regarded as one of the leading biomedical research institutions in the U.S. with top-tier faculty and programs in cancer, brain science, surgery and transplantation, trauma and emergency medicine, vaccine development and human genomics, among other centers of excellence. The School is not only concerned with the health of the citizens of Maryland and the nation, but also has a global presence, with research and treatment facilities in more than 35 countries around the world.


Office of Public Affairs
655 West Baltimore Street
Bressler Research Building 14-002
Baltimore, Maryland 21201-1559

Contact Media Relations
(410) 706-5260

Related stories

    Tuesday, January 28, 2020

    What Does the Future Hold for Gene Editing Technologies?

    University of Maryland School of Medicine (UMSOM) will be holding an expert panel today with Harvard Medical School Dean George Daley, MD, PhD, and UMSOM Dean E. Albert Reece, MD, PhD, MBA, to confront the promise and peril of the gene editing technology CRISPR. While the innovative technology holds enormous potential for treating and curing diseases caused by genetic mutations, it is also fraught with controversy as scientists and medical experts debate the full ethical implications of editing the genomes of human embryos to permanently alter the human species.